Enliven Therapeutics Unveils ELVN-001 Phase 1a Data Presentation
Enliven Therapeutics, Inc. (ELVN), an innovative clinical-stage precision oncology company, has recently made significant updates regarding their promising investigational drug, ELVN-001. This announcement comes as the data on ELVN-001 has been chosen for oral presentation at a prominent conference focused on chronic myeloid leukemia (CML). The European Society of Hematology International Chronic Myeloid Leukemia Foundation's 26th Annual John Goldman Conference is set for late September.
What Makes ELVN-001 Important for CML?
ELVN-001 is designed as a highly selective small molecule kinase inhibitor, marking a notable step forward in treatment options for CML patients. Its unique design specifically targets the BCR-ABL gene fusion, which is known to contribute to the progression of this cancer. This targeted strategy may bring new hope to individuals facing this difficult illness.
Key Details for the Upcoming Presentation
At the conference, Dr. Fabian Lang from Goethe University Hospital will present the updated information on ELVN-001. Here are the specifics you need to know:
- Title: Preliminary safety and efficacy of ELVN-001, a selective active site inhibitor of BCR::ABL1 in CML
- Session: Scientific Session 5: New drugs and combinations
- Date & Time: September 28, 2024, from 3:00 p.m. to 4:20 p.m. CEST, with Dr. Lang presenting from 3:35 p.m. to 3:50 p.m. CEST
How to Access the Presentation
If you’re interested in the details shared during the presentation, you can find a copy on Enliven Therapeutics' official website in the Program Presentations & Publications section, available after the conference concludes.
About Enliven Therapeutics
Enliven Therapeutics is at the leading edge of biopharmaceutical innovation. Their mission goes beyond just treating cancer; they aim to enhance the quality of life for patients. By focusing on small molecule inhibitors, they strive to meet both current and future needs of cancer patients, demonstrating a dedication to precision oncology. Through a deep understanding of validated biological targets and innovative chemical design, Enliven aims to develop therapies that have the potential to be best-in-class treatments in the oncology field.
Getting in Touch with Enliven Therapeutics
For those interested in investment opportunities, Enliven Therapeutics invites investors to reach out via their dedicated email address: ir@enliventherapeutics.com. Members of the media can also connect with the company by emailing media@enliventherapeutics.com for more information and assistance.
Frequently Asked Questions
What is the main aim of the ELVN-001 clinical trial?
The ELVN-001 clinical trial is designed to assess the safety and effectiveness of this targeted therapy for chronic myeloid leukemia.
Who will present the ELVN-001 data at the conference?
Dr. Fabian Lang from Goethe University Hospital will be sharing the updated Phase 1a data during the conference.
Where can I find the details of the presentation?
Details regarding the presentation can be accessed on Enliven Therapeutics’ website in the Program Presentations & Publications section after the conference.
What is the primary focus of Enliven Therapeutics?
Enliven Therapeutics focuses on discovering and developing small molecule inhibitors to enhance cancer treatment outcomes and improve patient quality of life.
How do I contact Enliven Therapeutics for investor relations inquiries?
Investors can reach out to Enliven Therapeutics via the email address ir@enliventherapeutics.com for any inquiries related to investor relations.
